ARLINGTON, Va.—According to the findings of a new report from BioInformatics LLC, total spending by research scientists on synthetic DNA oligonucleotides (oligos) is over US$700 million annually.
Continue reading below...
WebinarsAccelerating rare disease clinical trials
Explore how a rare kidney disease trial achieved faster patient enrollment with data-informed strategies and collaborative partnerships.
Read MoreIn the last decade, the demand for high quality oligonucleotides has risen with the focus on microarray technologies and antisense clinical research. Oligos represent a lucrative market for life science suppliers because these tools are critical to a wide variety of research applications and they are constantly being consumed with each experiment performed.
Because the overall market for oligos is considered mature, suppliers are challenged to distinguish their brand from the many others available to scientists.
BioInformatics—a market research and consulting firm—recently surveyed over 700 scientists who use synthetic oligos in their research. The results of this survey are presented in a new report, The Global Market for Synthetic Oligonucleotides.
This report follows a 2004 report, The U.S. Market for Synthetic Oligonucleotides, allowing the new report to offer some trend comparisons over the past two years.
For DNA oligos, respondents identified Integrated DNA Technologies as the dominant supplier. The other top suppliers of DNA oligos are Invitrogen, MWG Biotech, Operon Biotechnologies, and Sigma-Genosys (a division of Sigma-Aldrich).
